Capital Croissance
at 360°

Learn more >

Animal nutrition for scientist research

Status
Exited investments
Investments dates
June 2013 - October 2017
Turnover
€5-10m
Type of transaction
Majority MBO
Management
The management team, which consists of four people, is led by Georges Hasson
Intervention
Capital Croissance steered SAFE's exit from the Neovia Group (formerly InVivo NSA) alongside Unigrains and the management team and became its new majority shareholder. Capital Croissance will be able to actively support Safe in managing the "trimming" of the Neovia Group and in its development, particularly internationally and in its external growth strategy.

SAFE is a major player in formulating and manufacturing special foods and diets for the world of medical research. With over 400 clients (private and public laboratories, well-known private clients, etc.), the company is the market leader in France and generates about 20% of its turnover abroad.

Georges Hasson, Chairman: « We are very pleased to be associated with Capital Croissance and Unigrains in this new stage of our development. Our 5-6 year target is for SAFE to become the undisputed leader in Europe with significant positions in targeted emerging countries, particularly in Asia and Latin America. »